Lucid Diagnostics Files Definitive Proxy for Shareholder Vote on 100M Share Increase

summarizeSummary

Lucid Diagnostics has filed its definitive proxy statement, seeking shareholder approval to increase authorized common stock by 100 million shares, a crucial step for future financing amidst a 'going concern' warning.

check_boxKey Events

• Shareholder Meeting Scheduled

  The Annual Meeting of Stockholders is scheduled for June 24, 2026, with a record date of April 27, 2026.

• Proposed Increase in Authorized Common Stock

  Shareholders will vote on an amendment to increase authorized common stock by 100,000,000 shares, from 300,000,000 to 400,000,000. This authorization is vital for future financing and corporate flexibility.

• Potential Dilution

  If all 100 million newly authorized shares were issued, it would represent a potential dilution of approximately 51.2% based on the current 195,253,423 outstanding shares.

• Auditor Ratification

  The appointment of CBIZ CPAs P.C. as the independent registered certified public accounting firm for 2026 will be put to a shareholder vote.

auto_awesomeAnalysis

This definitive proxy statement formalizes Lucid Diagnostics' proposal to increase its authorized common stock by 100 million shares, from 300 million to 400 million. This move, previously disclosed in a preliminary filing, is critical for the company to address its 'going concern' warning and secure future financing, as highlighted in its recent 10-K. If approved, this authorization would enable substantial potential dilution, representing over 50% of current outstanding shares, but is necessary to provide the company with flexibility for equity awards, business financing, acquisitions, and strategic partnerships. Shareholders will vote on this and other proposals at the annual meeting on June 24, 2026.